Depression in patients with Parkinson's disease

International Journal of Geriatric Psychiatry

Volumn 14, Issue 9, 1999, Pages 711-718

  Cummings, Jeffrey L ^b   Masterman, Donna L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Antidepressant; Depression; Parkinson's disease; SSRI

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; GLAUCOMA; HUMAN; ORTHOSTATIC HYPOTENSION; PARALYTIC ILEUS; PARKINSON DISEASE; REVIEW; SIDE EFFECT; TREMOR; URINE RETENTION; VISUAL IMPAIRMENT;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; HUMANS; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; SEROTONIN UPTAKE INHIBITORS;

EID: 0032842303     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1166(199909)14:9<711::AID-GPS4>3.0.CO;2-1     Document Type: Review

References (52)

1. Andersen, J., Aabro, E., Gulmann, N., Hjelmsted, A. and Pedersen, H. E. (1980) Anti-depressive treatment in Parkinson's disease: A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA. Acta Neural. Scand. 62, 210-219.
2. Armin, S., Andreas, H., Hermann, W., Eckard, K., Wolfgang, G. and Otto, B. (1997) Pramipexole, a dopamine agonist, in major depression: Antidepressant effects and tolerability in an open-label study with multiple doses. Clin. Neuropharmacol. 20(Suppl. 1), S36-S45.
3. Bouchard, R. H., Pourcher, E. and Vincent, P. (1989) Fluoxetine and extrapyramidal side effects. Am. J. Psychiat. 146, 1352-1353.
4. Brooks, D. J., Abbott, R. J., Lees, A. J., Martignoni, E., Philcox, D. V., Rascol, O., Roos, R. A. and Sagar, H. J. (1998) A placebo-controlled evaluation of ripinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin. Neuropharmacol. 21, 101-107.
5. Brown, R. and Jahanshahi, M. (1995) Depression in Parkinson's disease: A psychosocial viewpoint. Adv. Neural. 65, 61-84.
6. Brown, R. G., MacCarthy, B., Gotham, A. M., Der, G. J. and Marsden, C. D. (1988) Depression and disability in Parkinson's disease: A follow up study of 132 cases. Psychol. Med. 18, 49-55.
7. Caley, C. F. and Friedman, J. H. (1992) Does fluoxetine exacerbate Parkinson's disease? J. Clin. Psychiat. 53, 278-282.
8. Cantello, R., Gilli, M., Riccio, A. and Bergamasco, B. (1986) Mood changes associated with 'end-of-dose deterioration' in Parkinson's disease: A controlled study. J. Neural. Neurosurg. Psychiat. 49, 1182-1190.
9. Celesia, G. G. and Wanamaker, W. M. (1972) Psychiatric disturbances in Parkinson's disease. Dis. Nerv. Syst. 33, 577-583.
10. Cummings, J. L. (1992) Depression and Parkinson's disease: A review. Am. J. Psychiat. 149, 443-454.
11. Cunningham, L. A. (1994) Depression in the medically ill: Choosing an antidepressant. J. Clin. Psychiat. 55, 90-97.
12. Dooley, M. and Markham, A. (1998) Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. Drugs Aging 12, 495-514.
13. Dunbar, G. C. (1995) Paroxetine in the elderly: A comparative meta-analysis against standard antidepressant pharmacotherapy. Pharmacology 51, 137-144.
14. Ehmann, T. S., Benninger, R. J., Gawel, M. J. and Riopelle, R. J. (1990) Depressive symptoms in Parkinson's disease: A comparison with control subjects. J. Geriatr. Psychiat. Neural. 2, 3-9.
15. Finley, P. R. (1994) Selective serotonin reuptake inhibitors: Pharmacologic profiles and potential therapeutic distinctions. Ann. Pharmacother. 28, 1359-1369.
16. Goetz, C. G., Tanner, C. M. and Klawans, H. L. (1984) Bupropion in Parkinson's disease. Neurology 34, 1092-1094.
17. Gotham, A. M., Brown, R. G. and Marsden, C. D. (1986) Depression in Parkinson's disease: A quantitative and qualitative analysis. J. Neural. Neurosurg. Psychiat. 49, 381-389.
18. Gottfries, C. G. (1996) Scandinavian experience with citalopram in the elderly. Int. Clin. Psychopharmacol. 11(Suppl. 1), 41-44.
19. Graeff, F. G., Guimaraes, F. S., De Andrade, T. G. and Deakin, J. F. (1996) Role of 5-HT in stress, anxiety, and depression. Pharmacol. Biochem. Behav. 54, 129-141.
20. Hauser, R. A. and Zesiewicz, T. A. (1997) Sertraline for the treatment of depression in Parkinson's disease. Mov. Disord. 12, 756-759.
21. Hesselink, J. M. K. (1993) Serotonin, depression, and PD. Neurology 43, 1624-1625.
22. Jansen Steur, E. N. H. (1993) Increase of Parkinson disability after fluoxetine medication. Neurology 43, 211-213.
23. Klaassen, T., Verhey, F. R., Sneijders, G. H., Rozendaal, N., de Vet, H. C. and van Praag, H. M. (1995) Treatment of depression in Parkinson's disease: A meta-analysis. J. Neuropsychiat. Clin. Neurosci. 7, 281-286.
24. Kostic, V. S., Djuricic, B. M., Covickovic-Sternic, N., Bumbasirevic, L., Nikolic, M. and Mrsulja, B. B. (1987) Depression and Parkinson's disease: Possible role of serotonergic mechanisms. J. Neural. 234, 94-96.
25. Laitinen, L. (1969) Desipramine in the treatment of Parkinson's disease. Acta Neural. Scand. 45, 109-113.
26. Lauterbach, E. C. and Duvoisin, R. C. (1991) Anxiety disorders in familial parkinsonism. Am. J. Psychiat. 148, 274.
27. Leo, R. J. (1996) Movement disorders associated with the serotonin selective reuptake inhibitors. J. Clin. Psychiat. 57, 449-454.
28. LeWitt, P. A. (1997) New options for treatment of Parkinson's disease. Baillieres Clin. Neural. 6, 109-123.
29. Liu, C. Y., Wang, S. J., Fuh, J. L., Lin, C. H., Yang, Y. Y. and Liu, H. C. (1997) The correlation of depression with functional activity in Parkinson's disease. J. Neural. 244, 493-498.
30. Maj, J., Rogoz, Z., Skuza, G. and Kolodziejczyk, K. (1997) Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J. Neural Transm. 104, 525-533.
31. Mayberg, H. S. and Solomon, D. H. (1995) Depression in Parkinson's disease: A biochemical and organic viewpoint. In Behav. Neural. Movement Disorders (W. J. Weiner and A. E. Lang, Eds). Advances in Neurology 65. Raven Press, New York, pp. 49-60.
32. Mayeux, R., Stern, Y., Cote, L. and Williams, J. B. (1984) Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 34, 642-646.
33. McCance-Katz, E. F., Marek, K. L. and Price, L. H. (1992) Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology 42, 1813-1814.
34. Menting, J. E., Honig, A., Verhey, F. R., Hartmans, M., Rozendaal, N., de Vet, H. C. and van Praag, H. M. (1996) Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: A qualitative analysis of the literature on their efficacy and side-effects. Int. Clin. Psychopharmacol. 11, 165-175.
35. Menza, M. A., Robertson-Hoffman, D. E. and Bonapace, A. S. (1993) Parkinson's disease and anxiety: Comorbidity with depression. Biol. Psychiat. 34, 465-470.
36. Rascol, O., Brooks, D. J., Brunt, E. R., Korczyn, A. D., Poewe, W. H. and Stocchi, F. (1998) Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov. Disord. 13, 39-45.
37. Richard, I. H., Kulan, R., the Parkinson's Study Group (1997) A survey of antidepressant drug use in Parkinson's disease. Neurology 49, 1168-1170.
38. Richelson, E. (1998) Pharmacokinetic interactions of antidepressants. J. Clin. Psychiat. 59(Suppl. 10), 22-26.
39. Santamaria, J., Tolosa, E. and Valles, A. (1986) Parkinson's disease with depression: A possible subgroup of idiopathic parkinsonism. Neurology 36, 1130-1133.
40. Silver, J. M. and Yudofsky, S. C. (1992) Drug treatment of depression in Parkinson's disease. In Parkinson's Disease: Neurobehavioral Aspects (S. J. Huber and J. L. Cummings, Eds). Oxford University Press, New York, pp. 240-254.
41. Srisurapanont, M. (1998) Response and discontinuation rates of newer antidepressants: A meta-analysis of randomized controlled trials in treating depression. J. Med. Assoc. Thai. 81, 387-392.
42. Standaet, D. G. and Stern, M. B. (1993) Update on the management of Parkinson's disease. Contemp. Clin. Neural. 77, 169-183.
43. Starkstein, S. E., Berthier, M. L., Bolduc, P. L., Preziosi, T. J. and Robinson, R. G. (1989) Depression in patients with early versus late onset of Parkinson's disease. Neurology 39, 1441-1445.
44. Starkstein, S. E., Preziosi, T. J., Bolduc, P. L. and Robinson, R. G. (1990) Depression in Parkinson's disease. J. Nerv. Ment. Dis. 178, 27-31.
45. Steibel, V. G. (1995) Maintenance electroconvulsive therapy for chronic mentally ill patients: A case series. Psychiatr. Serv. 46, 265-268.
46. Strang, R. R. (1965) Imipramine in treatment of Parkinsonism: A double-blind placebo study. Brit. Med. J. 2, 33-34.
47. Suchowersky, O. and deVries, J. D. (1990) Interaction of fluoxetine and selegiline. Can. J. Psychiat. 53, 571-572.
48. Tandberg, E., Larsen, J. P., Aarsland, D., Laake, K. and Cummings, J. L. (1997) Risk factors for depression in Parkinson's Disease. Arch. Neural. 54, 625-630.
49. Tom, T. and Cummings, J. L. (1998) Depression in Parkinson's disease. Pharmacological characteristics and treatment. Drugs Aging 12, 55-74.
50. Toyama, S. C. and Iacono, R. P. (1994) Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? Ann. Pharmacother. 28, 405-406.
51. Weiss, D. M. (1995) Serotonin syndrome in Parkinson disease. J. Am. Board Fam. Pract. 8, 400-402.
52. Willner, P. (1997) The mesolimbic dopamine system as a target for rapid antidepressarit action. Int. Clin. Psychopharmacol. 12(Suppl. 3), S7-S14.